Literature DB >> 23813332

Methodological considerations in quantification of 3'-deoxy-3'-[18F]fluorothymidine uptake measured with positron emission tomography in patients with non-small cell lung cancer.

Virginie Frings1, Adrianus J de Langen, Maqsood Yaqub, Robert C Schuit, Astrid A M van der Veldt, Otto S Hoekstra, Egbert F Smit, Ronald Boellaard.   

Abstract

PURPOSE: To investigate the effect of image-derived input functions (IDIF), input function corrections and volume of interest (VOI) size in quantification of [(18)F]FLT uptake in non-small cell lung cancer (NSCLC) patients. PROCEDURES: Twenty-three NSCLC patients were scanned on a HR+ scanner. IDIFs were defined over the aorta and left ventricle. Activity concentration and metabolite fraction were measured in venous blood samples. Venous blood samples at 30, 40 and 60 min after injection were used to calibrate the IDIF time-activity curves. Adaptive thresholds were used for VOI definition. Full kinetic analysis and simplified measures were performed.
RESULTS: Non-linear regression analysis showed better fits for the irreversible model compared to the reversible model in the majority. Calibrated and metabolite corrected plus plasma-to-blood ratio corrected input function resulted in high correlations between SUV and Patlak K i (Pearson correlation coefficients 0.86-0.96, p value < 0.001). No significant differences in correlation between SUV and Patlak K i were observed with variation of IDIF structure or VOI size.
CONCLUSIONS: Plasma-to-blood ratio correction, metabolite correction and calibration improved the correlation between SUV and Patlak K i significantly, indicating the need for these corrections when K i is used to validate semi-quantitative measures, such as SUV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23813332     DOI: 10.1007/s11307-013-0658-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  41 in total

1.  Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Authors:  Virginie Frings; Adrianus J de Langen; Egbert F Smit; Floris H P van Velden; Otto S Hoekstra; Harm van Tinteren; Ronald Boellaard
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  Validation of image-derived arterial input functions at the femoral artery using 18F-fluoride positron emission tomography.

Authors:  Tanuj Puri; Glen M Blake; Michelle L Frost; Amelia E B Moore; Musib Siddique; Gary J R Cook; Paul K Marsden; Ignac Fogelman; Kathleen M Curran
Journal:  Nucl Med Commun       Date:  2011-09       Impact factor: 1.690

3.  Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.

Authors:  J Scott Brockenbrough; Timothee Souquet; Janice K Morihara; Joshua E Stern; Stephen E Hawes; Janet S Rasey; Antoine Leblond; Linda W Wiens; Qinghua Feng; John Grierson; Hubert Vesselle
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

4.  Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.

Authors:  Roland Ullrich; Heiko Backes; Hongfeng Li; Lutz Kracht; Hrvoje Miletic; Kristina Kesper; Bernd Neumaier; Wolf-Dieter Heiss; Klaus Wienhard; Andreas H Jacobs
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

5.  3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.

Authors:  Albert J S Idema; Aswin L Hoffmann; Hieronymus D Boogaarts; Esther G C Troost; Pieter Wesseling; Arend Heerschap; Winette T A van der Graaf; J Andre Grotenhuis; Wim J G Oyen
Journal:  J Nucl Med       Date:  2012-10-17       Impact factor: 10.057

6.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

7.  Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: a report from the Pediatric Brain Tumor Consortium (PBTC).

Authors:  Gethin Williams; Frederic H Fahey; S Ted Treves; Mehmet Kocak; Ian F Pollack; James M Boyett; Larry E Kun; Tina Young Poussaint
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-19       Impact factor: 9.236

8.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

9.  Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.

Authors:  Adrianus J de Langen; Bianca Klabbers; Mark Lubberink; Ronald Boellaard; Marieke D Spreeuwenberg; Ben J Slotman; Remco de Bree; Egbert F Smit; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-18       Impact factor: 9.236

Review 10.  [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.

Authors:  Dmitry Soloviev; David Lewis; Davina Honess; Eric Aboagye
Journal:  Eur J Cancer       Date:  2011-12-29       Impact factor: 9.162

View more
  4 in total

Review 1.  Applications of PET imaging with the proliferation marker [18F]-FLT.

Authors:  M Peck; H A Pollack; A Friesen; M Muzi; S C Shoner; E G Shankland; J R Fink; J O Armstrong; J M Link; K A Krohn
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-03-04       Impact factor: 2.346

2.  Metabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.

Authors:  Lieke L Hoyng; Virginie Frings; Otto S Hoekstra; Laura M Kenny; Eric O Aboagye; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2015-04-23       Impact factor: 3.138

3.  Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis.

Authors:  Yvonne W S Jauw; Frederike Bensch; Adrienne H Brouwers; Otto S Hoekstra; Josée M Zijlstra; Simone Pieplenbosch; Carolien P Schröder; Sonja Zweegman; Guus A M S van Dongen; C Willemien Menke-van der Houven van Oordt; Elisabeth G E de Vries; Henrica C W de Vet; Ronald Boellaard; Marc C Huisman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-17       Impact factor: 9.236

4.  Application of [18F]FLT-PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2 mutation carriers.

Authors:  Liza Botros; Samara M A Jansen; Ali Ashek; Onno A Spruijt; Jelco Tramper; Anton V Noordegraaf; Jurjan Aman; Hans Harms; Frances S de Man; Marc C Huisman; Lan Zhao; Harm J Bogaard
Journal:  Pulm Circ       Date:  2021-06-30       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.